Welcome to Romgenix Pharmaceuticals, LLC

Romgenix Pharmaceuticals, LLC is engaged in research and development of targeted therapies and immunotherapies. Romgenix’s current efforts focus on Sodium Phenylbutyrate (PB) and related compounds for the treatment of malignant brain tumors. Romgenix was established in August of 2016, in order to engage in research, marketing, promotion, and sale of certain compounds which are known to effect the expression of genes. The main efforts are concentrated on FDA’s approval of a new treatment regimen for glioblastoma.